منابع مشابه
Peripheral neuropathy with infliximab therapy in inflammatory bowel disease.
To the Editor: Antitumor necrosis factor alpha (antiTNF ) agents have provided an important breakthrough in the management of patients with inflammatory bowel disease (IBD), leading to high remission rates, fistula closure, and improved quality of life. However, they are not without serious adverse effects, including lymphoma, infection, bowel obstruction, and neuropathy.1 This case report illu...
متن کاملManagement of inflammatory bowel disease in poor responders to infliximab
Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an immunomodulator, IFX dose escalation, or switching IFX for another antitumor necrosis factor-α drug, mainly adalimum...
متن کاملSafety of infliximab in patients suffering from inflammatory bowel disease.
Accessible online at: www.karger.com/dig Tumor necrosis factor-· (TNF-·) is a central cytokine in the inflammatory process associated with Crohn’s disease (CD). Infliximab, a chimeric IgG1 antibody directed against soluble and membrane-bound TNF-·, has shown efficacy both in luminal and fistulizing CD. It was approved in October 1998 by the US Food and Drug Administration for the treatment of m...
متن کاملInflammatory bowel disease of the lung: The role of infliximab?☆
Pulmonary extra-intestinal manifestations (EIM) of inflammatory bowel disease are well described with a variable incidence. We present a case of Crohn's disease with pulmonary EIM including chronic bronchitis with non-resolving bilateral cavitary pulmonary nodules and mediastinal lymphadenopathy successfully treated with infliximab. Additionally, we present a case summary from a literature revi...
متن کاملAccelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
AIM To study the safety and effectiveness associated with accelerated infliximab infusion protocols in patients with inflammatory bowel disease (IBD). METHODS Original protocols and infusion rates were developed for the administration of infliximab over 90-min and 60-min. Then the IBD patients on stable maintenance infliximab therapy were offered accelerated infusions. To be eligible for the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Chronic Disease
سال: 2019
ISSN: 2040-6223,2040-6231
DOI: 10.1177/2040622319838443